395 related articles for article (PubMed ID: 31836452)
41. Drug-Drug Interactions (DDIs) in Psychiatric Practice, Part 9: Interactions Mediated by Drug-metabolizing Cytochrome P450 Enzymes.
Preskorn SH
J Psychiatr Pract; 2020 Mar; 26(2):126-134. PubMed ID: 32134885
[TBL] [Abstract][Full Text] [Related]
42. Enzyme kinetics of cytochrome P450-mediated reactions.
Shou M; Lin Y; Lu P; Tang C; Mei Q; Cui D; Tang W; Ngui JS; Lin CC; Singh R; Wong BK; Yergey JA; Lin JH; Pearson PG; Baillie TA; Rodrigues AD; Rushmore TH
Curr Drug Metab; 2001 Mar; 2(1):17-36. PubMed ID: 11465149
[TBL] [Abstract][Full Text] [Related]
43. Impact of Lipid Partitioning on the Design, Analysis, and Interpretation of Microsomal Time-Dependent Inactivation.
Yadav J; Korzekwa K; Nagar S
Drug Metab Dispos; 2019 Jul; 47(7):732-742. PubMed ID: 31043439
[TBL] [Abstract][Full Text] [Related]
44. Therapeutic drugs that behave as mechanism-based inhibitors of cytochrome P450 3A4.
Zhou S; Chan E; Lim LY; Boelsterli UA; Li SC; Wang J; Zhang Q; Huang M; Xu A
Curr Drug Metab; 2004 Oct; 5(5):415-42. PubMed ID: 15544435
[TBL] [Abstract][Full Text] [Related]
45. Hydroxychloroquine is Metabolized by Cytochrome P450 2D6, 3A4, and 2C8, and Inhibits Cytochrome P450 2D6, while its Metabolites also Inhibit Cytochrome P450 3A
Paludetto MN; Kurkela M; Kahma H; Backman JT; Niemi M; Filppula AM
Drug Metab Dispos; 2023 Mar; 51(3):293-305. PubMed ID: 36446607
[TBL] [Abstract][Full Text] [Related]
46. Mechanism-based inactivation of cytochrome P450 enzymes: chemical mechanisms, structure-activity relationships and relationship to clinical drug-drug interactions and idiosyncratic adverse drug reactions.
Kalgutkar AS; Obach RS; Maurer TS
Curr Drug Metab; 2007 Jun; 8(5):407-47. PubMed ID: 17584015
[TBL] [Abstract][Full Text] [Related]
47. Evaluation of In Vitro Cytochrome P450 Inhibition and In Vitro Fate of Structurally Diverse N-Oxide Metabolites: Case Studies with Clozapine, Levofloxacin, Roflumilast, Voriconazole and Zopiclone.
Giri P; Naidu S; Patel N; Patel H; Srinivas NR
Eur J Drug Metab Pharmacokinet; 2017 Aug; 42(4):677-688. PubMed ID: 27853934
[TBL] [Abstract][Full Text] [Related]
48. Strategies for the development of highly selective cytochrome P450 inhibitors: Several CYP targets in current research.
Zhao L; Sun N; Tian L; Zhao S; Sun B; Sun Y; Zhao D
Bioorg Med Chem Lett; 2019 Aug; 29(16):2016-2024. PubMed ID: 31257085
[TBL] [Abstract][Full Text] [Related]
49. Cytochrome P450 Structure, Function and Clinical Significance: A Review.
Manikandan P; Nagini S
Curr Drug Targets; 2018; 19(1):38-54. PubMed ID: 28124606
[TBL] [Abstract][Full Text] [Related]
50. Statistical methods for analysis of time-dependent inhibition of cytochrome p450 enzymes.
Yates P; Eng H; Di L; Obach RS
Drug Metab Dispos; 2012 Dec; 40(12):2289-96. PubMed ID: 22942318
[TBL] [Abstract][Full Text] [Related]
51. An improved substrate cocktail for assessing direct inhibition and time-dependent inhibition of multiple cytochrome P450s.
Chen ZH; Zhang SX; Long N; Lin LS; Chen T; Zhang FP; Lv XQ; Ye PZ; Li N; Zhang KZ
Acta Pharmacol Sin; 2016 May; 37(5):708-18. PubMed ID: 27063220
[TBL] [Abstract][Full Text] [Related]
52. Atypical kinetics of cytochrome P450 enzymes in pharmacology and toxicology.
Leow JWH; Tang LWT; Chan ECY
Adv Pharmacol; 2022; 95():131-176. PubMed ID: 35953154
[TBL] [Abstract][Full Text] [Related]
53. Cytochrome P450 inactivation by pharmaceuticals and phytochemicals: therapeutic relevance.
Johnson WW
Drug Metab Rev; 2008; 40(1):101-47. PubMed ID: 18259986
[TBL] [Abstract][Full Text] [Related]
54. Metabolic drug-drug interaction potential of macrolactin A and 7-O-succinyl macrolactin A assessed by evaluating cytochrome P450 inhibition and induction and UDP-glucuronosyltransferase inhibition in vitro.
Bae SH; Kwon MJ; Park JB; Kim D; Kim DH; Kang JS; Kim CG; Oh E; Bae SK
Antimicrob Agents Chemother; 2014 Sep; 58(9):5036-46. PubMed ID: 24890600
[TBL] [Abstract][Full Text] [Related]
55. Fluorescence-Based High-Throughput Assays for Investigating Cytochrome P450 Enzyme-Mediated Drug-Drug Interactions.
He R; Dai Z; Finel M; Zhang F; Tu D; Yang L; Ge G
Drug Metab Dispos; 2023 Oct; 51(10):1254-1272. PubMed ID: 37349113
[TBL] [Abstract][Full Text] [Related]
56. Prediction of pharmacokinetic drug-drug interaction caused by changes in cytochrome P450 activity using in vivo information.
Hisaka A; Ohno Y; Yamamoto T; Suzuki H
Pharmacol Ther; 2010 Feb; 125(2):230-48. PubMed ID: 19951720
[TBL] [Abstract][Full Text] [Related]
57. Mechanism-based inactivation of cytochrome P450 enzymes by natural products based on metabolic activation.
Zhang T; Rao J; Li W; Wang K; Qiu F
Drug Metab Rev; 2020 Nov; 52(4):501-530. PubMed ID: 33043714
[TBL] [Abstract][Full Text] [Related]
58. The conduct of in vitro studies to address time-dependent inhibition of drug-metabolizing enzymes: a perspective of the pharmaceutical research and manufacturers of America.
Grimm SW; Einolf HJ; Hall SD; He K; Lim HK; Ling KH; Lu C; Nomeir AA; Seibert E; Skordos KW; Tonn GR; Van Horn R; Wang RW; Wong YN; Yang TJ; Obach RS
Drug Metab Dispos; 2009 Jul; 37(7):1355-70. PubMed ID: 19359406
[TBL] [Abstract][Full Text] [Related]
59. Prediction of human drug-drug interactions from time-dependent inactivation of CYP3A4 in primary hepatocytes using a population-based simulator.
Xu L; Chen Y; Pan Y; Skiles GL; Shou M
Drug Metab Dispos; 2009 Dec; 37(12):2330-9. PubMed ID: 19773538
[TBL] [Abstract][Full Text] [Related]
60. Contribution of metabolites to P450 inhibition-based drug-drug interactions: scholarship from the drug metabolism leadership group of the innovation and quality consortium metabolite group.
Yu H; Balani SK; Chen W; Cui D; He L; Humphreys WG; Mao J; Lai WG; Lee AJ; Lim HK; MacLauchlin C; Prakash C; Surapaneni S; Tse S; Upthagrove A; Walsky RL; Wen B; Zeng Z
Drug Metab Dispos; 2015 Apr; 43(4):620-30. PubMed ID: 25655830
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
